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Abstract
Background: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by vasculopathy and fibrosis,
which can be subclassified into diffuse cutaneous (dSSc) and limited cutaneous (lSSc) subtypes. Previous studies
suggest that an increase in monocytes can be a hallmark of various inflammatory diseases, including SSc. Our aim was
to evaluate circulating blood monocyte subpopulations (classical, intermediate and non-classical) of SSc patients and
their possible association with disease manifestations.
Methods: Fifty consecutive patients fulfilling the 2013 ACR/EULAR classification criteria for SSc were included in a
cross-sectional study. Monocyte subpopulations were identified based on their expression of CD64, CD14 and CD16,
evaluated by flow cytometry, and were correlated with the clinical characteristics of the patients; furthermore, the
expression of HLA-DR, CD163, CD169 and CD206 in the monocytes was studied. Thirty-eight age- and sex-matched
healthy individuals were recruited as a control group.
Results: SSc patients had an increased number of circulating peripheral blood monocytes with an activated
phenotypic profile compared to healthy subjects. Absolute counts of CD16+ (intermediary and non-classical)
monocyte subpopulations were higher in SSc patients. There was no association between monocyte
subpopulations and the clinical manifestations evaluated.
Conclusion: We identified higher counts of all monocyte subpopulations in SSc patients compared to the
control group. There was no association between monocyte subpopulations and major fibrotic manifestations.
CD169 was shown to be more representative in dSSc, being a promising marker for differentiating disease
subtypes.
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Background
Systemic sclerosis (SSc) is a chronic inflammatory sys-
temic disease, mainly characterized by expansion of the
secondary extracellular matrix due to an exaggerated pro-
tein production, especially collagen. Collagen is deposited
as a result of the abnormal interaction between endothe-
lial cells, mononuclear cells (lymphocytes and monocytes)
and fibroblasts. Monocytes express several receptors,
which monitor and detect environmental changes. Those
cells present great plasticity and heterogeneity and have
the ability to modify their functional phenotype in re-
sponse to stimulation [1]. There seems to be a relationship
between the monocytes/macrophages activation and mi-
gration [2, 3], and SSc pathogenesis [4].
Evidences from human and murine studies suggest that
an increase in monocytes can be an indicator of various
inflammatory diseases and that these cells could differenti-
ate into inflammatory or anti-inflammatory subgroups [5].
For almost two decades studies have shown the presence
of two subsets of cells: classical and non-classical mono-
cytes. Classical monocytes, characterized by expression of
CD14++CD16-, represent about 80% of all monocytes and
have phagocytic function, with production of reactive oxy-
gen species and secretion of pro- and anti-inflammatory
cytokines in response to agonist stimulation of toll-like
receptor-4 (TLR-4) [6]. Whereas non-classical monocytes,
which express CD16+, have a higher activity in response
to viruses and produce proinflammatory cytokines
through TLR-8 and TLR-9 [7, 8].
In recent years, a third group of monocytes has been
proposed, dividing the CD16+ population into non-
classical and intermediate monocytes (respectively,
CD14+/−CD16++ and CD14 + CD16+) [8–10]. These
CD16+ monocytes appear to be related to alternative ac-
tivated M2 macrophages, and their activation pathway
showed that they are associated with T helper (Th) 2 re-
sponse [5, 11]. The differences between these monocyte
subsets have been made clear, with distinct phenotypes
and different functions, such as defense against patho-
gens, homeostasis and tissue repair [9, 10, 12].
Evaluation of mannose receptor-1 (MRC1 or CD206)
and CD163 (macrophage scavenger receptors) that are
typical of M2 macrophage activation pathway, showed
an association of these markers with tissue repair and fi-
brosis [13], and in SSc patients those markers are associ-
ated with high pulmonary artery pressure and increased
mortality [14]. Other marker that may play a key role in
the monocyte activation present in SSc is CD169 (sialic
acid-binding Ig-like lectine I or Siglec-1), also known as
sialoadhesin, which has been shown to have a higher ex-
pression in a subset of SSc patients monocytes [15].
Monocytes of SSc patients have a greater expression of
these molecules, which is even higher in patients with
tissue disease and pulmonary artery hypertension.
Peripheral blood monocytes heterogeneity still lacks a
clear comprehension of its role in SSc pathophysiology
and clinical manifestations. The aim of our study was to
characterize the three monocytes subpopulations of SSc
patients, analyze the expression of CD163, CD169,
CD206 and HLA-DR (function and activation monocytes
receptors), and their association with clinical findings.
Methods
Patients
Fifty consecutive patients fulfilling the 2013 ACR/
EULAR classification criteria for SSc [16] were recruited
from the Outpatient Rheumatology Clinic of the Hos-
pital de Clínicas de Porto Alegre, Brazil. Clinical form of
disease was classified as diffuse SSc (dSSc) or limited
SSc (lSSc) according to the revised classification of
LeROY [17, 18]. Medications under use were obtained
from medical records and were confirmed during med-
ical appointments. Patients receiving immunosuppres-
sive drugs for SSc at the time of inclusion were carefully
evaluated since those medications can influence mono-
cytes counts and function [9]. Only patients that re-
ceived cyclophosphamide treatment at least 6 months
prior to the interview were included. Disease duration
was defined as the time interval since the onset of Ray-
naud’s phenomenon or skin symptoms (whichever came
first). Severity of skin involvement was assessed using
the modified Rodnan skin score [19]. Laboratory test re-
sults including serology, presence of autoantibodies and
pulmonary function tests such as assessment of lung dif-
fusion capacity for carbon monoxide (DLCO) and forced
vital capacity (FVC) performed in the period of 3
months before or after the peripheral blood sample col-
lection were obtained in medical records. Patients with
scleroderma in overlap syndrome with other connective
tissue disease and/or infectious diseases (HIV, hepatitis
C or B) were excluded.
Controls
Thirty-eight subjects age- and sex-matched to the SSc pa-
tients, with no previous history of autoimmune or
hematological diseases and a normal complete blood cell
(CBC) count (hemoglobin > 11.0 g/dl; white blood cells >
4 × 103/mm3 and < 12 × 103/mm3; and platelets > 150 ×
103/mm3) were recruited from a local blood donation cen-
ter and at a Primary Health Care Service unit. The criteria
for inclusion were the same as those used in blood
donation.
Study design
This was a monocentric cross-sectional study carried
out from October, 2016, to May, 2017.
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Flow cytometry protocol
Peripheral blood samples were collected in ethylenedi-
aminetetraacetic acid (EDTA) coated tubes. CBC was
performed in a Sysmex XE-2100™ (Sysmex, Kobe, JPN)
hematological counter and the total amount of periph-
eral blood monocytes was determined.
Flow cytometry immunophenotyping (FCI) to identify
and characterize monocyte subpopulations was per-
formed less than 4 h after blood sampling. About 1,000,
000 cells were placed into polystyrene tubes and were
subjected to surface staining by incubation with titrated
amounts of fluorochrome-conjugated monoclonal anti-
bodies (MoAbs) against CD14 APC-H7 (clone MφP9),
CD64 BV421 (clone 10.1), CD16 BV510 (clone 3G8),
HLA-DR PerCP-Cy5.5 (clone G46–6), CD206 APC
(clone 19.2), CD169 BB515 (clone 7–239) and CD163
PE (clone GHI/61) for 30 min at room temperature and
protected from light. All MoAbs were purchased from
BD Biosciences (San Diego, USA). Red blood cells were
lysed by incubation with 2 ml of lysing buffer (BD
Biosciences) for 10 min. Samples were washed and resus-
pended in phosphate buffered saline (PBS). At least 30,
000 gated monocytes were acquired in an 8-color BD
FACSCanto™ II flow cytometer (BD Biosciences) using
FACSDiva™ software (BD Biosciences). Flow cytometer
technical parameters were automatically set with BD
Cytometer Setup and Tracking Beads (BD Biosciences).
Daily internal quality control (QC) was performed with
IMMUNO-TROL Cells (BD Biosciences).
Phenotypic analysis of monocyte subpopulations
Figure 1 shows the gating strategy used. Initially, dou-
blets were excluded and total nucleated cells were se-
lected based on FSC (forward scatter) versus SSC (side
scatter) distribution. Monocytes were gated based on cell
size and complexity, as well as CD64+ expression [20],
and were plotted in a CD14 versus CD16 graph in order
to characterize all three monocyte subpopulations: clas-
sical monocytes (CD14++CD16-), intermediate mono-
cytes (CD14++CD16+) and non-classical monocytes
Fig. 1 Identification of monocyte subpopulations. a Cells were gated based on FSC (forward scatter) versus SSC (side scatter) distribution and
doublets were excluded. b Monocytes were gated based on cell size and complexity, as well as CD64 expression. c Monocyte subpopulations
were plotted in a CD14 versus CD16 expression in a representative healthy donor
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(CD14+/−CD16++). Fluorescence-minus-one (FMO)
methodology was used to differentiate autoflourescent
events from events with low concentrations of cell sur-
face markers [21]. All values obtained in this analysis
were considered FMO limit and all values of fluores-
cence above the limit were considered as true positive.
Percentage of expression and mean fluorescence inten-
sity (MFI) of any given marker within the defined
monocyte subpopulation were recorded. All FCI data
were analyzed using Kaluza Analysis Software (Beckman
Coulter Life Sciences, Indianapolis, USA) by two experi-
enced operators concomitantly.
Compliance with ethical standards
This study was approved by the Research Ethics Com-
mittee of the institution (CAAE number





Female gender (%) 47 (94.0) a 36 (94.7) a
Age (years) 57.2 ± 12.8 b 55.2 ± 11.4 b
European-derived (%) 40 (80) 24 (68.6)
Smoking status (%)
Never 25 (50) 23 (65.7)
Previous 21 (42) 30 (29.7)
Current 4 (8) 2 (5.7)
Disease duration (years) 15 (7–21)
Diffuse cutaneous involvement (%) 14 (28.0)
Modified Rodnan skin score 6 (2.8–10.3)




Diarrhea / constipation 21 (42.0)
DLCO (% predicted) 70.1 ± 16.3
Reduced DLCO (< 80% predicted) 52.9 (15.9)
FVC (% predicted) 79.2 ± 18.9
Reduced FVC (< 80% of predicted) 22 (44)
PASP 31.7 ± 14.4








Prednisolone < 20mg/day 6 (12)
Mycophenolate mofetil 4 (8)
Previous methotrexate administration 10 (20)
Previous rituximab administration 2 (4)
Previous cyclophosphamide administration 12 (24)
Data are shown as mean (± standard deviation), median (interquartile ranges) or number (n)
ANA anti-nuclear antibodies, Anti-dsDNA anti-double-stranded DNA, Anti-Scl70 antitopoisomeraseI, DLCO diffusion capacity of carbon monoxide, FVC forced vital
capacity, PASP arterial systolic pressure on Doppler echocardiography, RF rheumatoid factor, SSc systemic sclerosis
a Mann-Whitney test, p = 1.000
b Student’s T test, p = 0.448
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49299515.0.0000.5327) and was conducted in accordance
with the Declaration of Helsinki and current laws in
Brazil. Participants were included after written informed
consent.
Statistical analysis
Variables distribution was analyzed by Shapiro-Wilk’s
test and continuous variables were compared by Stu-
dent’s T or Mann–Whitney’s U test, whereas propor-
tions were compared by Pearson’s chi-square or Fisher’s
exact test. ANOVA or Kruskall-Wallis, with a Tukey or
Dunn correction test was used for multiple comparisons.
Pearson or Spearman correlation test was used to evalu-
ate association between variables. The statistical signifi-
cance level adopted was 5% (p < 0.05). Data analysis was
carried out with SPSS version 21.0® (IBM, Chicago,
USA) and Prisma 8 software (Graphpad Inc. San Diego,
USA).
Results
Patients and controls characteristics
Demographic data and clinical characteristics of SSc and
healthy control (HC) subjects are shown in Table 1. SSc
patients mean age was 57.2 years and 94% were female.
Limited form of disease was present in 72% of SSc pa-
tients. Median Rodnan skin score was 5 (2.0–8.0) in lSSc
patients and 11 (3.8–16.8) in the dSSc patients (p =
0.007). Pulmonary function also differed among disease
subgroups when comparing forced vital capacity
(FVC%predicted) results: lSSc subjects had higher mean
values when compared to dSSc patients (83.8 ± 17.4%
versus 67.5 ± 18.2%, p = 0.005).
Circulating monocyte subpopulations
Main results of monocytes evaluation are show in Fig. 2.
SSc patients had higher absolute and relative number of
circulating monocytes when compared to HC (459.6
(322.9–550.3)/mm3 versus 273.9 (179.3–352.2)/mm3,
p < 0.001), this difference remained significant when
comparing lSSc or dSSc patients with HC independently
(478.2 (342.9–555.5)/mm3 versus 273.9 (179.3–352.2)/
mm3, p < 0.001; and 387.4 (310.4–551.1)/mm3 versus
273.9 (179.3–352.2)/mm3, p = 0.002, respectively) (data
not shown). Among monocyte subpopulations, SSc pa-
tients had higher absolute counts of all subpopulations
(classical, intermediate and non-classical) when com-
pared to HC (classical monocytes 346.2 (260.9–450.8)/
mm3 versus 209.8 (146.1–287.1)/mm3, p < 0.001; inter-
mediate monocytes 38.2 (24.6–47.1)/mm3 versus 25.4
(12.6–41.2)/mm3, p = 0.005; non-classical monocytes
41.2 (20.8–58.3)/mm3 versus 28.3 (11.5–46.1)/mm3, p =
0.006) (data not shown). Regarding disease subtype, lSSc
patients presented increased absolute values of all mono-
cyte subpopulations when compared to HC (classical
monocytes 363.2 (262.9–451.8)/mm3 versus 209.8
(146.1–287.1)/mm3, p < 0.001 (A); intermediate mono-
cytes 38.5 (24.7–47.5)/mm3 versus 25.4 (12.6–41.2)/
mm3, p = 0.009 (B); non-classical monocytes 42.5 (20.8–
69.0)/mm3 versus 28.3 (11.5–46.1)/mm3, p = 0.005) (C).
While in dSSc patients, only classical monocytes had in-
creased absolute counts compared to HC (209.8 (146.1–
287.1)/mm3 versus 326.5 (231.2–461.9)/mm3, p = 0.003)
(A). There was no difference in monocytes absolute or
relative values between lSSc and dSSc subgroups (p =
0.450 and p = 0.914, respectively).
Circulating CD16+ monocyte subpopulations
When analyzing intermediate and non-classical mono-
cytes as a single group of CD16+ monocytes, we identi-
fied a higher absolute count of this subpopulation in
lSSc patients compared to HC (79.9 (53.4–103.5)/mm3
versus 55.9 (26.8–85.8)/mm3, p = 0.003) (Fig. 2d).
Monocyte subpopulations and clinical manifestations
Absolute counts of monocyte subpopulations did not
correlate with severity of cutaneous fibrosis assessed by
the modified Rodnan skin score, pulmonary involvement
assessed by DLCOc/VA, FVC and pulmonary artery sys-
tolic pressure, or disease duration when evaluated
among the total of patients or in lSSc and dSSc subtypes
(Fig. 3) (Additional files 1 and 2).
Fig. 2 Monocyte subpopulations according to their membrane expression of CD14 and CD16 in systemic sclerosis patients with limited (lSSc)
(n = 36) and diffuse (dSSc) (n = 14) subtypes, and in healthy controls (HC) (n = 38). The absolute count of all monocyte subpopulations - classical
a, intermediate b and non-classical c - is increased in lSSc compared to HC. d When analyzing intermediate and non-classical monocytes as a
single group of CD16+ monocytes, their absolute value is increased in lSSc compared to HC. *p < 0.05; **p < 0.01; ***p < 0.001
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Expression of surface receptors in monocyte
subpopulations
Results of surface expression of HLA-DR, CD206,
CD169 and CD163 receptors are shown in Fig. 4 and
Additional file 3. There were different expression pat-
terns among the evaluated monocyte subpopulations.
HLA-DR, an activation marker, was consistently
expressed in all monocytes from SSc and HC, and its in-
tensity of expression was higher in all monocyte subsets
from lSSc and dSSc patients when compared to control.
CD206 expression varied among the monocyte subsets,
the percentage of expression was higher in classical and
intermediate monocytes of SSc patients when compared
to HC and its MFI expression was lower in SSc as com-
pared to HC. When analyzing SSc subgroups, percentage
of CD206, the mannose receptor-1, expression was
higher only in classical monocytes of lSSc patients com-
pared to HC and in intermediate monocytes of lSSc and
dSSc compared to HC; whereas MFI of CD206
expression was lower in both lSSc and dSSc classical
monocytes when compared to HC. CD163, macrophage
scavenger receptor, was more expressed in classical (per-
centage and MFI) and intermediate (percentage) mono-
cytes of SSc patients as compared to HC. In subgroup
analysis, a difference in CD163 expression was demon-
strated in classical monocytes of lSSc subjects compared
to the HC group. CD169 receptor had a higher percent-
age of expression in SSc versus HC. When evaluating
SSc subtypes, classical and intermediate monocytes from
dSSc patients had higher MFI and percentage of CD169
expression than lSSc and HC, whereas non-classical
monocytes of dSSc patients had higher percentage of this
marker expression (Fig. 4).
Further analyses were performed for comparison of
the markers MFI of expression among the different
monocyte subpopulations. Except for CD163 expres-
sion, the monocyte subpopulations exhibited distinct
expression patterns when compared to one another,
Fig. 3 Correlations regarding the CD16+ monocyte subpopulation. The CD16+ monocyte subpopulation of SSc patients (n = 50) and in the
subgroup of patients presenting lSSc (n = 36) and dSSc (n = 14) was tested for association with cutaneous fibrosis assessed by the modified
Rodnan skin score (mRSS), pulmonary involvement assessed by DLCOc/VA and FVC. Disease duration was not associated with CD16 + values.
DLCO: diffusion capacity for carbon monoxide; FVC: forced vital capacity
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Fig. 4 Expression of surface receptors under study on monocyte subpopulations of systemic sclerosis patients divided by disease subtype in lSSc
(n = 36) and dSSc (n = 14) compared with healthy controls (HC) (n = 38). ANOVA with Tukey correction for symmetric distribution and Kruskal-
Wallis with Dunn correction for asymmetric distribution. MFI: mean fluorescence intensity. SSc: systemic sclerosis; HC: healthy controls; lSSc:
limited systemic sclerosis; dSSc: diffuse systemic sclerosis. *p < 0.05; **p < 0.01; ***p < 0.001
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which was similar among patients and HC subgroups
(Additional file 3).
Discussion
In our study, monocytes percentage and absolute count
were significantly increased in SSc patients as compared
to healthy subjects, regardless of disease subtype. Monocy-
tosis in SSc patients has been reported previously [5, 22].
Assessment of CD14 and CD16 receptors expression
allowed the identification of all three monocyte subpopu-
lations, as already described for healthy individuals and
some disease states [9, 23–25]. However, our study is the
first to describe these subpopulations in SSc patients,
using specific markers CD14 and CD16 for such distinc-
tion according to positivity and MFI of expression.
We identified an increase in all monocyte subpopula-
tions in SSc patients, which was even more significant in
patients with lSSc. Interestingly, lSSc patients showed an
increase of all three monocyte subpopulations compared
to controls, whereas in dSSc patients that increase was
at expense of classical monocytes, indicating that in this
form of disease the CD16+ monocyte subpopulations
does not increase. Recent studies in SSc patients have
shown an increase in CD16+ monocytes in the periph-
eral blood of these patients, however, these studies did
not distinguish between intermediate and non-classical
subpopulations [5, 22].
Previous studies have shown a significant correlation
of the absolute CD16+ monocyte subpopulation count
and severity of skin fibrosis and pulmonary fibrosis [5,
26]. In our study, we did not find correlations between
monocyte subpopulations and the clinical manifestations
evaluated. This difference may be related with inter-
mediate and non-classical monocyte subpopulations
grouped into CD16+ monocytes. Although differences
among intermediate and non-classical monocyte subsets
have been stablished [9, 10, 12], there is a strong prox-
imity between them [9], suggesting a direct developmen-
tal relationship, where gain of CD16 expression and
decrease in CD14 expression may be indicative of mat-
uration [27] and inflammatory activation for these cells
to be recruited to the periphery, where they begin to act
in localized inflammatory processes [5]. In addition,
there are resident tissue macrophages originated from
the yolk sac or from fetal liver progenitors [28], that
have long tissue life and self-renewing ability by in situ
proliferation, even in the absence of recruitment from
circulating monocytes [29–31]. The role of these macro-
phages in tissues during inflammation is still unclear
and further research is needed on the role of circulating
monocytes for their activation and proliferation, espe-
cially in inflammation models.
Our data corroborate the results obtained by Lescoat
et al. (2017) and Trombetta et al. (2018) concerning the
increased amount of circulating monocytes with CD16+
monocytes as the main representative monocyte subset
in SSc patients [5, 32]. Nevertheless, our results differ re-
garding correlations with clinical manifestations. The
fact that we did not find a correlation of monocyte sub-
sets with clinical manifestations reinforces the hypoth-
esis of cellular modulation and activation in loco, since
the different tissues are able to direct the inflammatory
response in order to exacerbate inflammation with pro-
inflammatory mediators or into resolution and repair
[33]. Hence, findings of monocyte/macrophage activa-
tion in the bloodstream may not be observed at the tis-
sue level, specifically, in internal organs affected by SSc.
HLA-DR is a cell activation marker, so it is consistent
to find a greater expression intensity of this marker in
patients with autoimmune diseases when compared to
normal subjects. We found an increase in MFI expres-
sion of HLA-DR in all monocyte subpopulations of SSc
patients compared to HC. MFI of HLA-DR expression
in CD16+ monocyte subpopulations (intermediate and
non-classical) was significantly higher than that of
CD16- classical monocytes, indicating a greater activa-
tion of CD16+ antigen-presenting cells, which is ex-
pected in an autoimmune state.
Other molecules, such as capture receptor CD163 and
CD206 were also associated with M2 macrophages and
could be involved into further differentiation processes. A
previous study comparing the expression of monocyte and
macrophage markers in peripheral blood and skin biopsy
specimens showed higher percentages of circulating cells
expressing CD204, CD163 and CD14, furthermore these
findings were correlated with skin involvement [22].
Additionally, circulating CD14+ monocytes/macro-
phages with CD206 coexpression have been shown to be
associated with pulmonary artery hypertension [13]. It has
also been shown that macrophages derived from circulat-
ing monocytes have coexpression of CD206, CD163 and
CD169, and that the expression of these markers is signifi-
cantly higher in patients with pulmonary interstitial dis-
ease [3]. In our study, a higher percentage of classical and
intermediate monocytes with CD206 expression were
identified in SSc patients compared to HC, which demon-
strates a greater amount of M2-like cells in those mono-
cyte subgroups of SSc patients.
Using a flow cytometry approach for assessing surface
markers from circulating monocytes/macrophages, Sol-
dano et al. (2018) demonstrated that SSc patients have
higher expression of the M2 related markers CD14,
CD206, CD163 and CD204; or that there is a coexpres-
sion of M1 and M2 surface markers in those cells [34];
providing evidence of plasticity in the expression of this
markers in circulating monocyte/macrophage and that
monocytes can evolve to exhibit features that are shared
by more than one macrophage population.
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Previous studies have suggested that CD169 may be a
phagocyte activity marker in inflammatory disorders.
CD169 has been identified as a marker of highly patho-
genic phagocytes in multiple sclerosis patients. Also, an
increased expression of Siglec-1 on peripheral blood
monocytes as well as its role in cell reactivity to autoan-
tigen has been shown in rheumatoid arthritis [35, 36].
CD169 expression in renal macrophages has been corre-
lated with proteinuria and tissue damage in glomerulo-
nephritis [37], however its expression in peripheral
blood cells was not assessed. CD169 expression has also
been associated with involvement in the immune system
regulation [38]. Biological functions of CD169 in macro-
phages and monocytes have yet to be elucidated. In our
study, there was an increased expression of CD169 in
classical monocytes from SSc patients compared to con-
trols, and CD169 expression was higher in all monocyte
subpopulations of dSSc patients compared to lSSc and
controls. This finding could represent a greater disease
activity in this subgroup of patients.
As to the use of medications, no association of these
with subpopulations of monocytes was found. There
were no differences between patients monocyte subpop-
ulations regarding corticosteroids use (n = 6). Patients
included in the study used low doses (less than 20 mg
per day), similar to previous reports [5].
Our study has some limitations. First of all, the patient
population appears to be relatively small. However, there
were many restrictions for patient inclusion in order to
minimize treatment interference and disease overlap.
Evaluation of exclusively circulating cells is also a limita-
tion. There is a need for simultaneous assessment of cir-
culating cells and tissue biopsies to better understand the
participation of macrophages derived from circulating
monocytes in tissue fibrosis. We have evidence that
monocytes and macrophages actually participate in SSc
pathogenesis and that there are slight differences between
tissues [1, 39], nevertheless, we need better strategies to
analyze these cells and studies assessing different tissues
and peripheral blood to determine whether these macro-
phages are derived from circulating monocytes or other
cells. In addition, our findings should be interpreted in
light of our sample characteristics. Considering the
pathophysiological and clinical changes observed in SSc
over time, different monocyte subpopulations could be
observed in early phases of the disease. Also, monocytes
activation may be influenced by different levels of im-
munosuppression and distinct mechanisms of action of
immunosuppressive drug treatment.
Conclusions
In conclusion, our results showed that SSc patients have
increased absolute counts of all three monocyte subpop-
ulations and that there is no difference among monocyte
subpopulations between lSSc and dSSc disease subtypes.
Monocytes from SSc patients presented a more activated
phenotypic profile which was suggestive of M2 cells,
with higher expression of CD206. Opposing to previous
reports, we did not find an association between mono-
cyte subpopulations and major fibrotic manifestations.
The intermediate and non-classical monocyte subpopu-
lations of SSc patients have increase expression of HLA-
DR. CD169 appears to be more representative marker
for dSSc subtype, however, more studies are necessary to
confirm that this is a good marker for differentiation of
disease subtype.
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